Aspen C Chun

Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships

Andrew S. Felts, Brian A. Chauder, K. Gregory, 2012, Molecular Pharmacology.

Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).

K. Gregory, J. Meiler, Z. Xiang, 2013, Journal of medicinal chemistry.

Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding

C. Lindsley, A. Mesecar, P. Hodder, 2013, Bioorganic & Medicinal Chemistry Letters.

Preparation of H,(4) PyrrolidineQuin-BAM (PBAM).

Tyler A. Davis, Aspen C Chun, Kenneth E. Schwieter, 2014, Organic syntheses; an annual publication of satisfactory methods for the preparation of organic chemicals.

The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate.

Alison R. Gregro, Andrew S. Felts, Anna L. Blobaum, 2019, Bioorganic & medicinal chemistry letters.

Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

Julie L. Engers, Andrew S. Felts, Anna L. Blobaum, 2018, ACS medicinal chemistry letters.